Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (NASDAQ: EXAS) is frequently in the news as a leading provider of cancer screening and diagnostic tests. Company announcements highlight developments across stool-based colorectal cancer screening, multi-cancer early detection, liver cancer surveillance, and precision oncology genomics. News coverage often reflects new clinical data, product launches, collaborations, and corporate transactions that shape the company’s role in cancer diagnostics.
Investors and clinicians following EXAS news can expect updates on the performance and adoption of the Cologuard and Cologuard Plus colorectal cancer screening tests, including real‑world adherence data and modeling studies that examine benefit‑to‑burden trade‑offs. Exact Sciences also reports on progress with its Cancerguard multi‑cancer early detection blood test, including study results from large prospective trials designed to support broader clinical use.
Another recurring theme in Exact Sciences news is the expansion of its precision oncology and surveillance portfolio. Releases describe pivotal and prospective studies of the Oncoguard Liver blood test for hepatocellular carcinoma surveillance, the Oncodetect molecular residual disease test in high‑risk breast cancer and other solid tumors, and the OncoExTra comprehensive genomic profiling assay for advanced cancers. These updates often come from major scientific meetings and include details on sensitivity, specificity, and prognostic performance.
Corporate and financial news items for EXAS include quarterly earnings releases, updated revenue and adjusted EBITDA guidance, participation in investor conferences, and strategic agreements such as the collaboration and license arrangement with Freenome for blood‑based colorectal cancer screening tests. A notable development disclosed in both press releases and SEC filings is the definitive agreement under which Abbott Laboratories plans to acquire Exact Sciences, subject to stockholder and regulatory approvals and other customary conditions.
This news page aggregates such announcements, offering a single place to review Exact Sciences’ latest clinical, product, financial, and transaction-related updates over time.
Exact Sciences (NASDAQ: EXAS) hailed passage of federal legislation creating a Medicare coverage pathway for multi-cancer early detection (MCED) tests on February 3, 2026. The law links coverage to FDA approval and subsequent CMS implementation, aiming to expand access for Medicare beneficiaries.
Exact Sciences noted its Cancerguard test is under continued clinical evaluation and cited modeling that suggests adding MCED to standard screening could reduce stage IV diagnoses by 45%.
Exact Sciences (Nasdaq: EXAS) said its Oncotype DX Breast Recurrence Score test has been used by more than 2 million patients worldwide as of February 3, 2026, guiding adjuvant therapy decisions for early-stage HR+, HER2- breast cancer.
The company reports an estimated 1.6 million patients avoided potentially unnecessary chemotherapy and U.S. lifetime savings of about $10,000 per patient, citing validation across diverse populations and a Category 1A NCCN recommendation.
Exact Sciences (NASDAQ: EXAS) presented first clinical results for the Oncodetect® MRD test in early triple-negative breast cancer (TNBC) at SABCS on December 11, 2025. In a 147-patient substudy of NSABP B-59, post-surgery ctDNA (MRD) positivity was associated with ~30-fold higher risk of distant recurrence versus MRD-negative patients, while 95% of MRD-negative patients remained distant recurrence-free at 3 years. Neoadjuvant therapy reduced ctDNA positivity from 95% pre-treatment to 9% post-treatment. Median follow-up was 37 months. The groups plan journal submission and a MolDx filing for Medicare coverage.
Exact Sciences (Nasdaq: EXAS) will present 10 abstracts at the 2025 San Antonio Breast Cancer Symposium, Dec 9-12, highlighting clinical validation and real‑world data across its Precision Oncology portfolio.
Key items include the first clinical validation of the Oncodetect test in triple‑negative breast cancer with highly sensitive MRD detection, a large ongoing NSABP B‑64 trial enrolling >1,800 patients with readouts starting in 2027, and multiple Oncotype DX studies showing improved outcomes, guideline‑concordant use across racial and ethnic groups, and an estimated >€60M chemotherapy cost savings in Ireland.
Abbott (NYSE: ABT) agreed to acquire Exact Sciences (NASDAQ: EXAS) for $105 per share, implying approximately $21 billion equity value and an estimated $23 billion enterprise value; Abbott will absorb about $1.8 billion of Exact Sciences net debt. Exact Sciences is projected to generate more than $3 billion in revenue this year with high‑teens organic growth and brings leading assets including Cologuard, Oncotype DX, Oncodetect and Cancerguard. Abbott expects the deal to be immediately accretive to revenue growth and gross margin. Closing is expected in Q2 2026, subject to shareholder and regulatory approvals.
Exact Sciences (NASDAQ: EXAS) said the Hart-Scott-Rodino waiting period expired for its exclusive U.S. license to Freenome’s blood-based colorectal cancer screening tests.
The license grants exclusive U.S. rights but remains conditional on Freenome’s test receiving first-line FDA approval. Exact Sciences updated 2025 guidance to reflect an initial $75 million cash payment, lowering full-year adjusted EBITDA guidance to $395–$405 million from $470–$480 million while leaving revenue guidance unchanged at $3.220–$3.235 billion.
Exact Sciences (NASDAQ: EXAS) announced pivotal ALTUS study results showing its Oncoguard Liver blood test outperformed ultrasound for hepatocellular carcinoma (HCC) surveillance in a prospective U.S. trial of >3,000 participants. The test met the primary endpoint, detecting early-stage HCC by Milan criteria 67% vs 22% for ultrasound, with very early-stage sensitivity 64% vs 9% and early-stage sensitivity 77% vs 36%. Oncoguard Liver specificity was 82%. Results will be presented as late-breaking data at AASLD The Liver Meeting on November 11, 2025 and are planned for peer-reviewed publication. The assay combines DNA methylation and protein markers and was developed with Mayo Clinic.
Exact Sciences (Nasdaq: EXAS) said company management will participate in the Jefferies London Healthcare Conference in London and invited investors to join a webcast of the fireside chat.
The event is scheduled for Tuesday, November 18, 2025 at 7:30 a.m. ET (12:30 p.m. GMT). The webcast is available in the investor relations section of Exact Sciences’ website at www.exactsciences.com.
Summary not available.
Exact Sciences (NASDAQ: EXAS) presented new real-world and modeling data at ACG 2025 showing the Cologuard mt-sDNA test and care-gap programs can raise colorectal cancer (CRC) screening and detection versus FIT.
Key findings: prior mt-sDNA users completed screening at 53.4% in a Medicare Advantage care-gap program vs 38.8% for other stool-test users; digital outreach raised completion odds by 129%. A cost-model (1M cohort) showed next-generation mt-sDNA screened 713,000 vs 318,000 for FIT, detected more advanced lesions (21,701 vs 3,328) and CRC cases (2,090 vs 440), and reduced total modeled costs ($1,388M vs $1,423M).
FAQ
What is the current stock price of Exact Sciences (EXAS)?
What is the market cap of Exact Sciences (EXAS)?
